Lumateperone 5-HT2A Ligand for Rapid Acute Depression Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Conventional antidepressants take weeks or months to achieve their full effects, and treatments like ketamine, while rapid-acting, have significant side effects and risks, making new, fast-acting methods for acute treatment of depression and anxiety urgently needed.
Innovation Solution
Substituted heterocycle fused gamma-carbolines, particularly lumateperone, act as 5-HT2A or 5-HT2A/D2 receptor ligands to enhance NMDA and AMPA currents, activate the mTOR signaling pathway, and reduce neuroinflammation, providing rapid antidepressant and anxiolytic effects without the adverse side effects of ketamine.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If conventional antidepressants are used, then they provide treatment for depression, but they take weeks or months to achieve full effects
Solution Approach 1:
The patent changes the pharmacological parameters by using 5-HT2A or 5-HT2A/D2 receptor ligands with specific binding characteristics (Ki values) that enable rapid antidepressant effects. Lumateperone exhibits potent 5-HT2A receptor antagonism (Ki=0.5 nM) and modulates dopamine receptor signaling, creating a new pharmacological profile that achieves rapid onset without the delayed action of conventional antidepressants.
2Speed
If ketamine is used for rapid-acting treatment, then it provides fast antidepressant effects, but it has significant side effects and risks
Solution Approach 1:
The patent introduces lumateperone as an intermediary substance that mediates rapid antidepressant effects through a different mechanism than ketamine. Instead of NMDA receptor antagonism like ketamine, lumateperone acts as a 5-HT2A receptor antagonist and dopamine receptor modulator, providing comparable rapid efficacy without ketamine's dissociative side effects, abuse potential, and cardiovascular risks.
3Speed
If 5-HT2A or 5-HT2A/D2 receptor ligands are used, then they provide rapid antidepressant effects, but their mechanism differs from conventional treatments
Solution Approach 1:
The patent demonstrates universality by showing that lumateperone, a single compound, can treat multiple conditions including acute depression, anxiety, and schizophrenia through its multi-target mechanism. It antagonizes 5-HT2A receptors, modulates dopamine D2 receptors, and stimulates glutamatergic NMDA NR2B receptors, providing broad therapeutic utility across different psychiatric disorders with a unified pharmacological approach.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Lumateperone exhibits immediate onset of action (hours to days) as a rapid-acting treatment for depression and anxiety, suitable for acute episodes, including suicidal ideation, without addiction risks, and reduces neuroinflammation.
Implementation Method 1
Lumateperone, having the formula: is a novel therapeutic agent with potent (Ki=0.5 nM) 5-HT2A receptor antagonism, activity as a mesolimbic/mesocortical-selective dopamine receptor protein phosphorylation modulator consistent with presynaptic D2 receptor partial agonism and postsynaptic D2 receptor antagonism (Ki=32 nM) in vivo
Implementation Method 2
exhibit a fast-acting antidepressant action via indirect dopamine D1 receptor-dependent enhancement of NMDA and AMPA currents coupled with activation of the mTOR (e.g., mTORC1) signaling pathway
Implementation Method 3
paralleled by anti-inflammatory properties
Data Source
AI summary
The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT2A or 5-HT2A/D2 receptor ligand, e.g. lumateperone.